Monitoring the safety of nilotinib in patients with chronic myeloid leukemia
Journal
Macedonian pharmaceutical bulletin
Date Issued
2019
Author(s)
Pendovska M
Panovska I
Kalcev G
Zisovska E
Mihajloska E
Filkova S
Abstract
The aim of the study was to evaluate the safety profile of nilotinib administered to chronic myeloid leukemia (CML) at patients. The
study was conducted from March 2018 to May 2019 and it included 20 patients with CML in chronic phase. Of these 20 patients, 17 had
previously been treated with imatinib and 3 with hydroxyurea. The mean duration of treatment with Nilotinib was 6.75 months. In nine
patients treated with nilotinib (400 mg), 55% complained of fatigue, 33% of headache and 22.2% of pruritus. In five patients treated with
Nilotinib (600 mg), 20% complained of headache, 40% of fatigue and 20% of pruritus. In addition, in six patients treated with nilotinib
(800 mg), 50% complained of headache and fatigue, 17% with pruritus and visual disorder was observed in 20% of cases. In the study,
the adverse reactions were observed between the age of 20 and 40 and it was 7.1%, in contrast to the group of patients between the age of
40 and 60 where the incidence of adverse reactions was 21.42%. The incidence of adverse reactions in patients in the age group over 60
years it was 57.1%. In terms of gender, the incidence of adverse reactions was equal to 50% for both men and women. In conclusion, this
study showed that treatment with nilotinib was well tolerated, with adverse reactions of an easy degree. Future evaluation is necessary in
order to understanding the adverse reaction of nilotinib in comparison with other tyrosine kinase inhibitors.
study was conducted from March 2018 to May 2019 and it included 20 patients with CML in chronic phase. Of these 20 patients, 17 had
previously been treated with imatinib and 3 with hydroxyurea. The mean duration of treatment with Nilotinib was 6.75 months. In nine
patients treated with nilotinib (400 mg), 55% complained of fatigue, 33% of headache and 22.2% of pruritus. In five patients treated with
Nilotinib (600 mg), 20% complained of headache, 40% of fatigue and 20% of pruritus. In addition, in six patients treated with nilotinib
(800 mg), 50% complained of headache and fatigue, 17% with pruritus and visual disorder was observed in 20% of cases. In the study,
the adverse reactions were observed between the age of 20 and 40 and it was 7.1%, in contrast to the group of patients between the age of
40 and 60 where the incidence of adverse reactions was 21.42%. The incidence of adverse reactions in patients in the age group over 60
years it was 57.1%. In terms of gender, the incidence of adverse reactions was equal to 50% for both men and women. In conclusion, this
study showed that treatment with nilotinib was well tolerated, with adverse reactions of an easy degree. Future evaluation is necessary in
order to understanding the adverse reaction of nilotinib in comparison with other tyrosine kinase inhibitors.
File(s)![Thumbnail Image]()
Loading...
Name
Safty of Nilotinob.pdf
Size
650.33 KB
Format
Adobe PDF
Checksum
(MD5):c7a666f7153840e2f7008a741e9a0ce3